Morphic only had eyes for Eli Lilly. While some takeover tales have casts of Shakespearean breadth, Lilly’s $3.2 billion Morphic buyout is a simpler story of two companies gradually closing the gap ...
Monday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion. Morphic is a biopharmaceutical company ...
AbbVie is ditching work on all the alpha V beta 6 (αvβ6) inhibitors that it paid $20 million to license from Morphic Therapeutic in 2020. The Big Pharma is culling the work because of a suspected ...
INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic ...
INDIANAPOLIS (WISH) — Eli Lilly and Co. announced Monday morning that it has reached an agreement to acquire biopharmaceutical company Morphic. The Massachusetts-based Morphic describes itself as a ...
-Reported positive results from EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis (UC)- -Enrollment on target in EMERALD-2 phase 2b global randomized trial of MORF-057 in UC- -GARNET phase 2 ...
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic ...
BOSTON, Aug. 5, 2025 /PRNewswire/ -- Morphic Medical, an innovative MedTech company that has pioneered minimally invasive treatment of obesity and cardiometabolic disorders, today announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results